grant

Modeling Core

Organization NORTHWESTERN UNIVERSITYLocation CHICAGO, UNITED STATESPosted 17 Jan 2018Deadline 31 Dec 2027
NIHUS FederalResearch GrantFY20262019 novel corona virus2019 novel coronavirus2019-nCoVAdoptedAssayAwardBioassayBiocompatible MaterialsBiological AssayBiological MarkersBiomaterialsBloodBlood Reticuloendothelial SystemBronchoalveolar Lavage FluidCOVID associated pneumoniaCOVID induced pneumoniaCOVID infected patientCOVID patientCOVID pneumoniaCOVID positive patientCOVID related pneumoniaCOVID-19COVID-19 associated pneumoniaCOVID-19 induced pneumoniaCOVID-19 infected patientCOVID-19 patientCOVID-19 pneumoniaCOVID-19 positive patientCOVID-19 related pneumoniaCOVID-19 viral pneumoniaCOVID-19 virusCOVID19 patientCOVID19 positive patientCOVID19 virusCV-19CalciumCalcium ChannelCalcium Channel Antagonist ReceptorCalcium Channel Blocker ReceptorsCalcium Ion ChannelsCell BodyCellsCessation of lifeClinicalClinical DataClinical Decision Support SystemsClinical TreatmentCoV-2CoV2CollaborationsCoronavirus Infectious Disease 2019Critical IllnessCritically IllDataData SetDeathDimensionsDiseaseDisorderDoseDrug KineticsDrug TherapyEnsureFibrosing AlveolitisGenerationsGoalsHeterogeneityImmune responseInfectionInterventionInvestigatorsLung Tissue FibrosisMachine LearningMeasuresMedicineModelingMolecularMultiomic DataNasal EpitheliumNatureNosocomial pneumoniaOutcomePathogenesisPatientsPharmacodynamicsPharmacokineticsPharmacological TreatmentPharmacotherapyPhasePhysiciansPhysiologicPhysiologicalPneumoniaPublishingPulmonary FibrosisRandomization trialResearch PersonnelResearchersSARS corona virus 2SARS-CO-V2SARS-COVID-2SARS-CoV-2SARS-CoV-2 associated pneumoniaSARS-CoV-2 induced pneumoniaSARS-CoV-2 infected patientSARS-CoV-2 patientSARS-CoV-2 pneumoniaSARS-CoV-2 positive patientSARS-CoV-2 related pneumoniaSARS-CoV-2 viral pneumoniaSARS-CoV2SARS-associated corona virus 2SARS-associated coronavirus 2SARS-coronavirus-2SARS-related corona virus 2SARS-related coronavirus 2SARSCoV2SamplingSevere Acute Respiratory Coronavirus 2Severe Acute Respiratory Distress Syndrome CoV 2Severe Acute Respiratory Distress Syndrome Corona Virus 2Severe Acute Respiratory Distress Syndrome Coronavirus 2Severe Acute Respiratory Syndrome CoV 2Severe Acute Respiratory Syndrome-associated coronavirus 2Severe Acute Respiratory Syndrome-related coronavirus 2Severe acute respiratory syndrome associated corona virus 2Severe acute respiratory syndrome coronavirus 2Severe acute respiratory syndrome related corona virus 2Space ModelsSystemSystems BiologyTechnologyTestingTherapeutic StudiesTherapy ResearchVDCCVoltage-Dependent Calcium ChannelsWorkWuhan coronavirusbio-markersbiologic markerbiological materialbiomarkerbiomarker identificationclinical decision-makingclinical interventionclinical phenotypeclinical therapycohortcommunity acquired pneumoniacommunity associated pneumoniacomputer based predictioncoronavirus disease 2019coronavirus disease 2019 associated pneumoniacoronavirus disease 2019 induced pneumoniacoronavirus disease 2019 infected patientcoronavirus disease 2019 patientcoronavirus disease 2019 pneumoniacoronavirus disease 2019 positive patientcoronavirus disease 2019 related pneumoniacoronavirus disease 2019 viruscoronavirus disease associated pneumoniacoronavirus disease induced pneumoniacoronavirus disease infected patientcoronavirus disease patientcoronavirus disease pneumoniacoronavirus disease positive patientcoronavirus disease related pneumoniacoronavirus disease-19coronavirus disease-19 patientcoronavirus disease-19 pneumoniacoronavirus disease-19 viruscoronavirus infectious disease-19coronavirus patientdiffuse interstitial pulmonary fibrosisdiscrete timedrug interventiondrug treatmentfibrosis in the lungfield based datafield learningfield studyfield testhCoV19health care settingshealthcare-associated pneumoniahigh dimensional datahospital acquired pneumoniahospital associated pneumoniahost responseidentification of biomarkersidentification of new biomarkersidiopathic pulmonary fibrosisimmune system responseimmunoresponseimproved outcomeinhibitorlife-threatening COVIDlife-threatening COVID-19life-threatening SARS-CoV-2life-threatening coronavirus diseaselife-threatening coronavirus disease 2019life-threatening severe acute respiratory syndrome coronavirus 2lung fibrosismachine based learningmachine learned algorithmmachine learning algorithmmachine learning based algorithmmachine statistical learningmarker identificationmolecular biomarkermolecular markermortalitymultidimensional datamultidimensional datasetsmultiomicsmultiple omic datamultiple omicsnCoV2new approachesnew drug targetnew druggable targetnew markernew pharmacotherapy targetnew therapeutic targetnew therapy targetnovelnovel approachesnovel biomarkernovel drug targetnovel druggable targetnovel markernovel pharmacotherapy targetnovel strategiesnovel strategynovel therapeutic targetnovel therapy targetpanomicspathogenpatient infected with COVIDpatient infected with COVID-19patient infected with SARS-CoV-2patient infected with coronavirus diseasepatient infected with coronavirus disease 2019patient infected with severe acute respiratory syndrome coronavirus 2patient with COVIDpatient with COVID-19patient with COVID19patient with SARS-CoV-2patient with coronavirus diseasepatient with coronavirus disease 2019patient with severe acute respiratory distress syndrome coronavirus 2pharmaceutical interventionpharmacological interventionpharmacological therapypharmacology interventionpharmacology treatmentpharmacotherapeuticspneumonia due to COVIDpneumonia due to COVID-19pneumonia due to SARS-CoV-2pneumonia due to coronavirus diseasepneumonia due to coronavirus disease 2019pneumonia due to severe acute respiratory syndrome coronavirus 2pneumonia in COVIDpneumonia in COVID-19pneumonia in SARS-CoV-2pneumonia in coronavirus diseasepneumonia in coronavirus disease 2019pneumonia in severe acute respiratory syndrome coronavirus 2pneumonia modelpneumonia modelspneumonia therapypneumonia treatmentpost-COVIDpost-COVID-19post-coronavirus disease 2019predictive modelingrandomized trialresponseserious COVIDserious COVID-19serious SARS-CoV-2serious coronavirus diseaseserious coronavirus disease 2019serious severe acute respiratory syndrome coronavirus 2severe COVIDsevere COVID-19severe COVID19severe SARS-CoV-2severe acute respiratory syndrome coronavirus 2 associated pneumoniasevere acute respiratory syndrome coronavirus 2 induced pneumoniasevere acute respiratory syndrome coronavirus 2 infected patientsevere acute respiratory syndrome coronavirus 2 patientsevere acute respiratory syndrome coronavirus 2 pneumoniasevere acute respiratory syndrome coronavirus 2 positive patientsevere acute respiratory syndrome coronavirus 2 related pneumoniasevere coronavirus diseasesevere coronavirus disease 19severe coronavirus disease 2019severe severe acute respiratory syndrome coronavirus 2single cell analysisstatistical and machine learningsuccesstargeted drug therapytargeted drug treatmentstargeted therapeutictargeted therapeutic agentstargeted therapytargeted treatmenttherapeutic targettooltool developmenttranscriptomicstreat pneumoniatrial regimentrial treatmentventilation
Sign up free to applyApply link · pipeline · email alerts
— or —

Get email alerts for similar roles

Weekly digest · no password needed · unsubscribe any time

Full Description

Project Summary/Abstract – Modeling Core
The Modeling Core, as part of SCRIPT, aimed to apply machine learning approaches to clinical and -omics data

generated by the SCRIPT projects and cores to develop a models of severe pneumonia and identify novel

biomarkers and therapeutic targets. Using an iterative systems biology approach, we generated a detailed

model, published in Nature, of how severe SARS-CoV-2 pneumonia, in contrast with severe pneumonia due to

other pathogens, possesses a peculiar host response pathobiology that explains its propensity to cause

prolonged critical illness. Importantly, SCRIPT’s model predicted the efficacy of an experimental pharmacologic

intervention in SARS-CoV-2 pneumonia – the CRAC channel inhibitor Auxora. In this renewal, Super-SCRIPT

(SCRIPT2) will continue to leverage serial sampling of biological materials (bronchoalveolar lavage fluid, nasal

epithelium, blood) paired with cutting-edge multi-omics technologies and deep clinical phenotyping to develop

models of pneumonia pathogenesis which could augment clinical decision making. We used clinical and -omics

data collected and generated during the first cycle of this award to generate preliminary data for the renewal. We

discretized time in the ICU and related physiological measures on a per-day basis, similar to how physicians

view and treat patients with severe pneumonia in the ICU. Our novel approach overcomes a critical limitation in

the application of machine learning approaches to clinical data, which often do not take into account interventions

that can change the course of the disease and typically focus only on clinical state at presentation and ultimate

outcome, analogous to drawing a line between two points. We generated a low-dimensional interpretable latent

space model of clinical states in patients with severe pneumonia. We show that transitions between these clinical

states are different in patients with SARS-CoV-2 pneumonia and other types of pneumonia. By projecting results

of -omics assays onto this clinical latent space, we propose to identify biomarkers associated with favorable and

unfavorable clinical transitions. We will use this latent space model of severe pneumonia to test the hypothesis

that machine learning approaches can identify interpretable cellular and molecular biomarkers of

favorable and unfavorable clinical transitions during the clinical course of severe pneumonia. We will

test this hypothesis in three interrelated Specific Aims:

Aim 1: To generate an interpretable latent space model of clinical states and transitions (disease

trajectories) in patients with severe pneumonia using data collected within SCRIPT2.

Aim 2: To identify cellular and molecular biomarkers and clinical interventions predictive of transitions

between unfavorable and favorable clinical states in patients with severe pneumonia using data

collected within SCRIPT2.

Aim 3: To generalize models generated using SCRIPT2 to external datasets.

Grant Number: 5U19AI135964-09
NIH Institute/Center: NIH

Principal Investigator: LUIS AMARAL

Sign up free to get the apply link, save to pipeline, and set email alerts.

Sign up free →

Agency Plan

7-day free trial

Unlock procurement & grants

Upgrade to access active tenders from World Bank, UNDP, ADB and more — with email alerts and pipeline tracking.

$29.99 / month

  • 🔔Email alerts for new matching tenders
  • 🗂️Track tenders in your pipeline
  • 💰Filter by contract value
  • 📥Export results to CSV
  • 📌Save searches with one click
Start 7-day free trial →